Infimab, the first Remicade (Infliximab) biosimilar revealed to be successful in treating inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, ulcerative colitis, psoriasis and psoriatic arthritis, was recently launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh by Ranbaxy Laboratories Ltd. Infimab, also known as BOW015, is entering the Indian market thanks to a partnership with EPRIRUS Biopharmaceuticals, Inc. EPRIRUS is a US and Swiss-based company that is developing and commercializing biosimilar monoclonal antibodies. Ranbaxy, the biggest pharmaceutical company in India, operates in more than 150 countries worldwide by providing generic drugs. The company's values are delivering value to stakeholders and inspiring people to innovate and exceed barriers. Through Infimab, Ranbaxy is officially entering into the mAb (Monoclonal Antibodies) biologics field and it will seek to provide improved access to quality medicines that can manage serious health conditions such as IBD. BOW015 is a biosimilar version of Infliximab (Remicade is its marketed name) and it has shown to be effective based on positive Phase 1 and Phase 3 clinical reports. The phase 3 trial comparing BOW015 to Remicade demonstrated their similarity, and no meaningful differences regarding safety and immunogenicity were found. Rajeev Sibal, Ranbaxy Vice President & Country Head-India Region said in a press release: "Infimab offers a new opportunity in the management of conditions like rheumatoid arthritis. The product has been developed as per global standards and delivers a similar clinical outcome to the innovator. It will be available in India at a very significant discount as compared to the innovator drug.